Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436 CH)
Watchlist
91
Analysis
Health Care
•
China
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. manufactures and markets Chinese traditional medicines, including Pientzehuang, Pientzehuang capsules, Pientzehuang lozenge, cough syrup, and other related products.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
30 Mar 2023 08:55
China Traditional Chinese Medicine (TCM) Industry - TCM Is Becoming Indispensable in the Portfolio
The current policy environment in China indicates that TCM is core asset of pharmaceuticals, not innovative drug R&D. It''s time to take TCM...
Xinyao (Criss) Wang
Follow
330 Views
Share
bullish
•
Thematic (Sector/Industry)
•
08 Mar 2023 08:55
China's 2023 Government Work Report in 14th NPC - The Highlights and the Outlook
We analyzed our interpretation on China's 2023 Government Work Report in 14th NPC, including GDP growth, CPI, fiscal/monetary policy, valuation...
Xinyao (Criss) Wang
Follow
382 Views
Share
bearish
•
Shanghai Haohai Biological Tec
•
05 Mar 2023 09:00
China Healthcare Weekly (March.3) - TCM New Policy, Pfizer to Acquire Seagen, Haohai Biological
New favorable policy for TCM industry was released. We analyzed our top picks. Pfizer is in talks to acquire Seagen, but we're conservative about...
Xinyao (Criss) Wang
Follow
492 Views
Share
bullish
•
Quantitative Analysis
•
19 Dec 2022 08:05
Northbound Flows (Dec 16th): CMB, Shanghai Intl Airport, Tongwei
We analyzed the Shanghai/Shenzhen Connect Scheme for last week and highlight flows for CMB, Shanghai Intl Airport, Tongwei.
Ke Yan, CFA, FRM
Follow
379 Views
Share
bearish
•
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
•
21 Nov 2022 09:01
Zhangzhou Pientzehuang Pharmaceutical (600436.CH) - Disappointing Performance Is Just the Beginning
The investment logic of PienTzeHuang has changed, with more downside in valuation ahead. It's time to think about long logic from a broader...
Xinyao (Criss) Wang
Follow
345 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.41.3
x